Last Price$175.1(6.4%)
Market Cap$13.6B
LTM Cash Return on Invested Capital (CROIC)
19.5%
5Y avg
23.0%
Medical - Devices industry
median
(35.7%)
Stock quality & Intrinsic value
6/10
0.1% undervalued
Align Technology, Inc. Cash Return on Invested Capital (CROIC)
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Return on Invested Capital (CROIC) | 31.0% | 4.2% | (58.2%) | 61.3% | 32.0% | 81.2% | 127.8% | 48.3% | 29.8% | 56.5% | 71.8% | 56.4% | 41.1% | 38.5% | 37.0% | 50.4% | 30.0% | 32.5% | 9.9% | 20.5% |
Overvalued or undervalued?
Check the intrinsic value for ALGN
and see if it's the right time to invest.
Align Technology, Inc. (ALGN) Cash Return on Invested Capital (CROIC) comparison analysis
General
LTM Cash Return on Invested Capital (CROIC)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Align Technology, Inc.ALGN
19.5%
3.4%
26.0%
11.5%
Median Peer Set
8.6%
5.6%
126.3%
12.7%
DexCom, Inc.DXCM
21.1%
11.3%
(1.4%)
14.3%
Insulet CorporationPODD
20.1%
30.0%
4,364.6%
12.2%
Stryker CorporationSYK
15.4%
10.2%
(5.8%)
13.2%
Abbott LaboratoriesABT
12.0%
4.6%
134.5%
31.9%
Edwards Lifesciences CorporationEW
9.1%
(9.4%)
202.2%
76.7%
Boston Scientific CorporationBSX
8.1%
17.6%
16.7%
11.1%
STERIS plcSTE
7.9%
3.6%
257.9%
7.4%
Medtronic plcMDT
7.9%
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc.ZBH
5.9%
6.5%
253.2%
13.8%
Koninklijke Philips N.V.PHG
2.6%
(0.8%)
118.1%
(3.9%)
ALGN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 172.8 0.0% | 207.1 19.8% | 206.4 (0.4%) | 284.3 37.8% | 304.0 6.9% | 312.3 2.7% | 387.1 23.9% | 479.7 23.9% | 560.0 16.7% | 660.2 17.9% | 761.7 15.4% | 845.5 11.0% | 1,079.9 27.7% | 1,473.4 36.4% | 1,966.5 33.5% | 2,406.8 22.4% | 2,471.9 2.7% | 3,952.6 59.9% | 3,734.6 (5.5%) | 3,862.3 3.4% |
| Cost of Goods Sold (COGS) | 57.5 | 63.8 | 64.8 | 75.0 | 78.9 | 78.8 | 83.7 | 118.5 | 143.7 | 162.1 | 183.2 | 205.4 | 264.6 | 356.5 | 518.6 | 662.9 | 708.7 | 1,017.2 | 1,100.9 | 1,155.4 |
% margin | 115.3 66.7% | 143.3 69.2% | 141.6 68.6% | 209.3 73.6% | 225.1 74.1% | 233.5 74.8% | 303.4 78.4% | 361.3 75.3% | 416.4 74.3% | 498.1 75.4% | 578.4 75.9% | 640.1 75.7% | 815.3 75.5% | 1,116.9 75.8% | 1,447.9 73.6% | 1,743.9 72.5% | 1,763.2 71.3% | 2,935.4 74.3% | 2,633.8 70.5% | 2,706.9 70.1% |
| Operating Expenses | 105.5 | 140.9 | 179.1 | 175.4 | 203.4 | 266.2 | 204.8 | 270.9 | 294.2 | 336.9 | 384.9 | 451.5 | 566.4 | 763.3 | 981.3 | 1,229.4 | 1,376.1 | 1,959.0 | 1,979.7 | 2,063.5 |
| Research & Development Expenses (R&D) | 15.8 | 18.6 | 18.5 | 25.7 | 26.2 | 22.3 | 26.0 | 37.2 | 42.9 | 44.1 | 52.8 | 61.2 | 75.7 | 97.6 | 128.9 | 157.4 | 175.3 | 250.3 | 305.3 | 346.8 |
| Selling, General & Administrative Expenses (SG&A) | 89.8 | 122.3 | 160.6 | 151.5 | 177.2 | 174.3 | 178.8 | 231.3 | 247.9 | 292.8 | 332.1 | 390.2 | 490.7 | 665.8 | 852.4 | 1,072.1 | 1,200.8 | 1,708.6 | 1,674.5 | 1,703.4 |
% margin | 9.8 5.7% | 2.4 1.2% | (37.5) (18.2%) | 33.9 11.9% | 15.5 5.1% | (34.0) (10.9%) | 102.7 26.5% | 90.4 18.8% | 85.6 15.3% | 94.2 14.3% | 193.6 25.4% | 188.6 22.3% | 248.9 23.1% | 353.6 24.0% | 466.6 23.7% | 407.5 16.9% | 293.6 11.9% | 976.4 24.7% | 642.6 17.2% | 643.3 16.7% |
| Interest Income | 0.7 | 1.9 | 3.2 | 4.2 | 3.1 | 0.6 | 0.6 | 0.6 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.6 | 12.5 | 3.1 | 3.1 | 5.4 | 17.3 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 2.1 | 0.0 | 0.0 | 0.0 | 0.0 | 11.2 | 0.0 | 0.0 | 0.0 | 36.0 | 5.4 | 0.0 |
| Pre-tax Income | 9.8 | 2.7 | (34.1) | 37.0 | 17.1 | (33.9) | 102.0 | 89.9 | 84.3 | 93.1 | 190.4 | 186.1 | 242.6 | 364.8 | 466.7 | 562.7 | 378.9 | 1,012.4 | 599.1 | 641.2 |
% effective tax rate | 1.0 10.2% | 1.3 48.2% | 0.8 (2.4%) | 1.2 3.3% | (62.9) (368.4%) | (2.6) 7.7% | 27.8 27.2% | 23.2 25.8% | 25.6 30.4% | 28.8 31.0% | 44.5 23.4% | 42.1 22.6% | 51.2 21.1% | 130.2 35.7% | 57.7 12.4% | 112.3 20.0% | (1,396.9) (368.6%) | 240.4 23.7% | 237.5 39.6% | 196.2 30.6% |
% margin | 8.8 5.1% | 1.4 0.7% | (35.0) (16.9%) | 35.7 12.6% | 80.0 26.3% | (31.3) (10.0%) | 74.3 19.2% | 66.7 13.9% | 58.7 10.5% | 64.3 9.7% | 145.8 19.1% | 144.0 17.0% | 189.7 17.6% | 231.4 15.7% | 400.2 20.4% | 442.8 18.4% | 1,775.9 71.8% | 772.0 19.5% | 361.6 9.7% | 445.1 11.5% |
| EPS | 0.15 | 0.02 | (0.55) | 0.53 | 1.20 | (0.45) | 0.98 | 0.86 | 0.73 | 0.80 | 1.81 | 1.80 | 2.38 | 2.89 | 5.00 | 5.57 | 22.55 | 9.78 | 4.62 | 5.82 |
| Diluted EPS | 0.14 | 0.02 | (0.55) | 0.50 | 1.18 | (0.45) | 0.95 | 0.83 | 0.71 | 0.78 | 1.77 | 1.77 | 2.33 | 2.83 | 4.92 | 5.53 | 22.41 | 9.69 | 4.61 | 5.81 |
% margin | 9.8 5.7% | 12.9 6.2% | (23.6) (11.4%) | 47.2 16.6% | 29.9 9.8% | (20.8) (6.7%) | 116.2 30.0% | 90.4 18.8% | 102.1 18.2% | 178.1 27.0% | 211.4 27.8% | 206.6 24.4% | 272.9 25.3% | 391.4 26.6% | 521.3 26.5% | 666.0 27.7% | 387.2 15.7% | 976.4 24.7% | 755.4 20.2% | 799.0 20.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Align Technology, Inc.'s Cash Return on Invested Capital (CROIC)?
As of today, Microsoft Corp's last 12-month Cash Return on Invested Capital (CROIC) is 19.5%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Cash Return on Invested Capital (CROIC) for Align Technology, Inc. have been 20.0% over the past three years, and 24.2% over the past five years.
2) Is Align Technology, Inc.'s Cash Return on Invested Capital (CROIC) Good?
As of today, Align Technology, Inc.'s Cash Return on Invested Capital (CROIC) is 19.5%, which is higher than industry median of (35.7%). It indicates that Align Technology, Inc.'s Cash Return on Invested Capital (CROIC) is Good.